Abstract 1657P
Background
Pancreatic ductal adenocarcinoma (PDAC) represents the fourth highest rate of cancer-related deaths worldwide. The absence of early symptoms, early metastasis, and inefficient systemic therapies lead to a fatal prognosis for PDAC patients. Currently, surgical resection is the only curative option. However, it is often linked to severe postoperative complications and a considerable tumor recurrence rate. Therefore, identifying the resistance mechanisms of PDAC and developing targeted therapies is crucial.
Methods
Mutant KRAS and its effector Pdk1 play a major role in PDAC carcinogenesis. Previous works showed that Pdk1 deletion causes impairment of PDAC cell proliferation in vitro and in vivo. However, a minor subpopulation of cells continues to proliferate. To investigate this resistance, a genome wide CRISPR/Cas9 knockout screen was performed. Members of SAGA and Mediator complexes were among the top hits of the screen. The CRISPR knockouts of these genes were generated in the bulk PDAC epithelial cell line and in two single cell clones - one resistant and one sensitive to Pdk1 deletion. Clonogenic assays were performed to analyze the proliferation of the knocked-out cells, while RNA sequencing was conducted to investigate the differentially expressed genes.
Results
In the CRISPR/Cas9 knockout screen, members of SAGA and Mediator complexes showed enrichment in Pdk1 deletion resistant clones. Amongst all hits, significant proliferation of the Usp22- and Atxn7L3- as well as Med13- and Med16-knockout in the Pdk1 deleted PDAC cells was observed, with the strongest effect in the resistant clone. Several enhanced or downregulated hallmark pathways were observed in the knocked-out cells, providing insight into possible resistance mechanisms of the PDAC.
Conclusions
The results of the RNA sequencing of both SAGA and Mediator knocked-out cells showed an enhancement of the Hedgehog signalling, a pathway reported in the initiation of a growing number of cancers. The results of this research suggest furthermore, that the loss of the connecting units Atxn7L3 and Med16 promotes an unhinged transcription activity of the enzymatically active SAGA and Mediator complexes and leads to an enhanced PDAC cell proliferation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
German Research Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1569P - The CODRP model for predicting drug sensitivity in patient-derived 3D gastric cancer cells
Presenter: Dong Woo Lee
Session: Poster session 22
1571P - Exploration of immune and metabolism gene signature for prognosis of esophageal carcinoma and establishment of a combined prediction model
Presenter: Hao Wu
Session: Poster session 22
1572P - Impact of HER2 and PD-L1 co-expression in Claudin18.2 positive resectable gastroesophageal cancers
Presenter: Antonella Cammarota
Session: Poster session 22
1573P - Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC
Presenter: Baosheng Li
Session: Poster session 22
1575P - Factors associated with uptake of adjuvant nivolumab in a nationwide esophageal cancer patient cohort
Presenter: Rob Verhoeven
Session: Poster session 22
1577P - Prior antibiotic administration disrupts outcomes of PD-1 blockade in advanced gastric cancer by altering gut microbiome and systemic immune response
Presenter: Chang Gon Kim
Session: Poster session 22
1578P - Effect of immune checkpoint inhibitors in metastatic gastric cancer: A real-world evidence study
Presenter: Francesco Puccetti
Session: Poster session 22